TG Therapeutics, Inc. Q2 2026 Earnings Call Summary
TG Therapeutics said Q2 2026 results reflected record new patient starts and broader physician adoption of BRIUMVI. The company raised full-year 2026 U.S. BRIUMVI net revenue guidance to $890 million to $905 million and expects about $950 million global revenue. It reported $55 million in R&D charges tied to subcutaneous manufacturing and cited Phase III data for a 600 mg single-infusion schedule.
How this was made
The 30-second read
Why it matters
Traders can update expectations for 2026 revenue trajectory and the probability-weighted timing of the subcutaneous Phase III sub-readout, which the company frames as a key market share catalyst.
Market read
The most tradable items are the raised 2026 revenue guidance range, the stated Q4 as the primary driver of second-half growth, and the planned subcutaneous Phase III timing window.
What to watch
The article does not provide specific subcutaneous pricing, and competitive responses (including payer behavior in Part D) could materially affect realized margins and switch rates.
Background
TG Therapeutics’ Q2 2026 earnings call focused on BRIUMVI commercial momentum, a subcutaneous ublituximab roadmap, and expansion of the company’s autoimmune franchise via azer-cel.
Ticker impact
TG Therapeutics raised 2026 U.S. BRIUMVI net revenue guidance to $890M-$905M and expects $1B annualized run-rate by end-2026.
Moderately positive bias for shares into the next catalyst window (Q4 growth and year-end/early-2027 subcutaneous Phase III readout).
The article discloses specific, time-bound financial guidance and development milestones tied to BRIUMVI, which typically drives re-rating versus prior expectations. However, it is a call summary rather than a new regulatory/approval event, limiting immediate upside magnitude.
Market effects
Reinforces competitive pressure in anti-CD20 and subcutaneous switching dynamics, potentially affecting read-across expectations for other MS and autoimmune franchises.
Primarily U.S. revenue guidance focus, with ex-U.S. margin mix noted (lower-margin partner sales).
Global revenue outlook and partnership milestone expectations may influence sentiment around cross-border commercialization models in specialty pharma.
Counterpoint
Raised guidance could be partially offset by ongoing manufacturing-related R&D charges and execution risk around subcutaneous Phase III timing and uptake.
Key entities
- companyTG Therapeutics, Inc.
Raised 2026 BRIUMVI guidance, highlighted record patient starts, and outlined subcutaneous and azer-cel expansion plans.
- productBRIUMVI
Ublituximab franchise central to guidance, subcutaneous expansion, and switching dynamics versus competing anti-CD20 therapies.
- companyRoche
Referenced as OCREVUS competitor in switching and market share discussion.
- companyNeuraxpharm
Partnership referenced for ex-U.S. revenue drivers and milestone payments.
- productazer-cel
Management highlighted expansion into multiple B-cell-mediated diseases as a future value pillar.
